Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported an insider transaction involving stock options and common shares. On March 4, 2026, she exercised 9,500 stock options (labeled as Stock Options) at a reported exercise price of $0.0000 per share, leaving her with 211,500 stock options held directly following the exercise.
The same day, she executed a series of open-market sales totaling 19,000 shares of Common Stock, with reported per‑share prices including $486.4229 and up to $497.0500. After these sales, she held 130 shares of Common Stock directly. Additional indirect Common Stock holdings are reported as 166 shares held by spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. A footnote states that the option exercise and related share sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of 101.8000. On the same date, he then sold 4,910 shares of common stock at a reported price per share of 489.0200. After these transactions, his directly owned common stock holdings were 12,670 shares.
UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on March 4, 2026. He exercised a stock option for 2,000 options, labeled as an exercise or conversion of a derivative security, resulting in 2,000 options held afterward.
On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of $101.8000 per share, bringing his direct common stock holdings to 10,480 shares. He then executed an open-market sale of 2,000 common shares at a weighted average price of $489.4197 per share, leaving 8,480 directly held shares.
A footnote states that his direct holdings include 880 additional common shares to be issued on or about July 8, 2026 from previously vested RSUs for which receipt was deferred. Indirectly, 8,200 common shares are held by a trust and 5,800 common shares are held through a Family LLC associated with him.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options for 20 shares on March 4, 2026, converting them into common stock at a price of $119.76 per share. He then sold 20 common shares in an open-market transaction at a weighted average price of $490.1685 per share.
The option exercise and subsequent sale were carried out under a pre-arranged Rule 10b5-1 trading plan that Causey entered into on September 30, 2025. The sale occurred in multiple trades, with individual prices ranging from $490.12 to $490.21, and left him with 4,190 common shares held directly.
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.
Morgan Stanley Smith Barney LLC files Form 144 to sell common shares of UTHR via stock option exercises. The notice lists multiple proposed sales dated 03/05/2026 and earlier, with individual transactions showing share quantities (8,300 and 11,000) and aggregate proceeds listed per trade.
United Therapeutics Corporation submitted a Form 144 notice of proposed sale of securities by an insider. The filing lists a planned stock option exercise and proposed sale of 20 common shares on 03/04/2026 for cash to the issuer. The filing also discloses three recent open-market sales by Christopher Causey: $520,000 for 1,000 shares on 02/25/2026, $510,000 for 1,000 shares on 01/06/2026, and $500,014.60 for 1,000 shares on 01/02/2026.
United Therapeutics reported a Form 144 notice proposing the sale of 2,000 common shares. The filing lists the proposed sale date as 03/04/2026, arising from a stock option exercise with proceeds to be received in cash. The record shows a prior sale of 910 shares on 12/18/2025 for $455,533.17.
United Therapeutics Corp director Jan Malcolm reported an open-market sale of 50 shares of common stock on March 3, 2026 at a price of $509.20 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Malcolm beneficially owned 170 shares of common stock.